US could scrap health warnings on HRT
The Food and Drug Administration (FDA) is convening a panel on Thursday afternoon, featuring several proponents of the therapy, to discuss whether federal guidelines overstate the risk to women.
Currently, HRT and other treatments that use oestrogen warn that it could increase the risk of strokes, blood clots, dementia and breast cancer, and should not be used to prevent cardiovascular disease or dementia.
However, Marty Makary, the head of the FDA, has claimed the risks of the treatment – used for hot flushes and other menopausal symptoms – are exaggerated and that its benefits are 'overwhelming'.
'For decades, hormone replacement therapy for women … has helped women alleviate the symptoms of menopause, including hot flushes, dryness, mood swings, weight gain and poor sleep quality, to name a few,' Dr Makary said.
When treatment begins 10 years ahead of the menopause, HRT could reduce the risk of cognitive decline and Alzheimer's and prevent osteoporosis and cardiovascular disease, he added.
No opportunity for public comment
Dr Makary blamed declining use of HRT on a clinical trial in the early 2000s – halted after recording increased risks of breast cancer and strokes – which he said had not been replicated in later studies.
He has previously claimed on a podcast there is 'no medication that improves the health outcomes of a population' apart from antibiotics.
The issue is still controversial in the medical community, however.
Critics said the panel includes a number of physicians who agree with Dr Makary's stance on HRT, and does not have the opportunity for public comment, according to The New York Times.
'This is not like any other public meeting held by the FDA in the past,' said Diana Zuckerman, president of the National Centre for Health Research think tank.
'No one in the audience is being allowed to speak. No one can ask questions,' she continued, saying most participants had a positive view of hormone therapy.
'Menopause should not be medicalised'
The description of the event on the FDA website reads: 'Hormone replacement therapy has long been an important treatment option for women to alleviate symptoms of menopause, among other potential health benefits.
'Over the last two decades, however, HRT has been surrounded by confusing narratives about potential risks.'
Earlier this week, the American Journal of Physicians published an editorial concluding HRT brought limited benefits and significant harms.
'Menopause is a positive life experience for many women and should not be medicalised,' its authors wrote.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
44 minutes ago
- Daily Mail
Trump demands UK pharmaceutical giants to lower drug costs sparking fears NHS could pay the price if they refuse
Donald Trump has demanded UK pharmaceutical giants lower prices for America and suggested charging others to make up the difference. He said if they didn't, the US would deploy 'every tool in our arsenal' to protect families from 'continued abusive drug prices', sparking fears the NHS will end up paying more. Mr Trump suggested he would use tariffs to push through higher prices if countries resisted. In May Mr Trump signed an executive order demanding drugmakers cut US medicine prices to match those abroad. Yesterday in a letter to 17 pharma companies he said he expected them to deliver on measures by September 29. He asked them to apply 'most favoured nation' pricing to Medicaid, the US health programme for people on low incomes. Mr Trump also asked drugmakers to offer new medicines at the same price in the US as in other developed countries. He said: 'Our citizens pay massively higher prices than other nations pay for the same exact pill... subsidizing socialism aboard [abroad].' British pharma companies AstraZeneca and GSK were among the recipients. Others included Eli Lilly, Johnson & Johnson, Pfizer and Sanofi. The UK Government said it would 'continue to work closely with the US to get the best deal for our pharma industry and deliver mutual benefits for both our countries'.
Daily Mail
4 hours ago
- Daily Mail
New study shows using marijuana triples risk of developing cancer
People who frequently use marijuana more than triple their risk of developing oral cancer , a new study found. About half of US adults say they have ever tried marijuana, with about 17.7million suffering from symptoms of cannabis use disorder (CUD) . The condition requires a formal diagnosis after fulfilling several criteria, such as using the drug despite the negative impacts it has on a person's life and relationships. University of California , San Diego researchers followed 45,000 people, some with cannabis use disorder, for five years. They discovered that daily smokers were 3.25 times more likely to develop oral cancer than those without the disorder. Dr Raphael Cuomo, an anesthesiology professor at UC San Diego School of Medicine who led the analysis, said: 'Cannabis smoke contains many of the same carcinogenic compounds found in tobacco smoke, which have known damaging effects on the epithelial tissue that lines the mouth.' Cannabis smoke packs a heavy load of toxic chemicals and carcinogens, about 2,600 of them, similar to tobacco smoke. But researchers are only recently getting a fuller understanding of what those chemicals are. They now know that marijuana smoke contains hundreds of polycyclic aromatic hydrocarbons (PAHs), benzene, and ammonia. These chemicals adhere to mucus membranes in the mouth, enabling carcinogens to seep into oral tissue. Meanwhile, THC, the psychoactive chemical in marijuana, can suppress crucial immune system pathways that would typically patrol for, and kill, those rogue cells. Of the more than 45,000 patients included in the study, 949 had cannabis use disorder. The group that did not smoke or smoked only occasionally remained either weed free or only occasional users over the five-year study. Over 97 percent were still abstinent or infrequent users by the time researchers followed up. During the study, 106 patients were diagnosed with oral cancer. Among people without CUD, the rate of oral cancer was 0.23 percent, which matches general population rates. However, among participants with CUD, 0.74 percent developed oral cancer. Oral cancer includes cancerous growths that develop in the mouth and throat, including the lips, tongue, gums, the floor of the mouth and the roof of the mouth. About one in 59 men and 1 in 139 women will develop oral cancer at some point in their lives. Oral cancers account for about three percent of cancers diagnosed in the US every year, with about 58,500 diagnoses and 12,250 deaths annually. Researchers said their findings will have implications for cancer screening practices in primary care and mental health settings, as patients with CUD often present with overlapping social and behavioral risk factors, including tobacco use, alcohol use, and a lower likelihood of engaging in preventive healthcare. People with CUD who were also tobacco users were 6.24 times more likely to get oral cancer. Age also played a role, with each additional year of age increasing cancer risk by about four times per year. Like tobacco smokers, marijuana smokers see damage to their lung and throat cells, leading to abnormal cell growth that can cause cancer and tissue changes. Those effects can occur in people who are not tobacco smokers, though, indicating that marijuana smoke can be just as harmful on its own as cigarette smoke. Dr Cuomo said: 'These findings add to a growing body of evidence suggesting that chronic or problematic cannabis use may contribute to cancer risk in tissues exposed to combustion products.' Their findings were published in the journal Preventive Medicine Reports . In the United States, marijuana is fully legal for recreational and medicinal use in 29 states. It is entirely illegal in four states. The majority of the public, about 88 percent , supports legalization, according to the Pew Research Center. But public health experts are raising concerns over potential long-term effects, of which scientists still do not have a complete understanding. In June, University of California researchers reviewed 24 studies involving 200million people to investigate the relationship between weed and cardiovascular disease, stroke and acute coronary syndrome (ACS) - a group of heart conditions in which there is reduced or blocked blood flow to the heart, such as a heart attack. They found there was a 29 percent higher risk of ACS among cannabis users, a 20 percent higher risk for stroke and double the risk of dying from cardiovascular disease, which includes coronary artery disease, heart failure and irregular heartbeats. Last month, findings from an FDA-run clinical trial were released, investigating dangerous liver enzyme spikes in people who consumed cannabis. The results showed that eight users of CBD, the substance derived from the hemp plant that's free of the psychoactive chemical THC, developed enzyme spikes above the safe threshold, raising the risk of chronic liver damage or failure. Seven people dropped out due to liver concerns between weeks three and four. However, everyone's liver tests normalized after quitting CBD. Meanwhile, regular use of potent cannabis in adolescence has been linked to long-term changes in brain structure, particularly in the prefrontal cortex, the region responsible for decision-making, emotional regulation, and impulse control. This is also the age when many psychotic disorders first appear. THC may trigger schizophrenia or psychotic episodes in individuals with genetic predispositions. A 2022 review by University of Bath researchers, which analyzed 20 studies involving 120,000 people, found users of high-potency cannabis were four times more likely to develop addiction and three to five times more likely to suffer a psychotic break compared to those using lower-potency strains. Earlier this year, a report in JAMA Network Open found that emergency room visits in Ontario, Canada, linked to schizophrenia in marijuana users tripled after legalization. Between 2006 and 2022, the rate of schizophrenia among those with cannabis use disorder climbed from four percent to over 10 percent. In contrast, just 0.6 percent of non-users developed the condition.
Daily Mail
4 hours ago
- Daily Mail
Dirty habit followed by 18million Americans TRIPLES the risk of getting cancer
People who frequently use marijuana more than triple their risk of developing oral cancer, a new study found. About half of US adults say they have ever tried marijuana, with about 17.7million suffering from symptoms of cannabis use disorder (CUD). The condition requires a formal diagnosis after fulfilling several criteria, such as using the drug despite the negative impacts it has on a person's life and relationships. University of California, San Diego researchers followed 45,000 people, some with cannabis use disorder, for five years. They discovered that daily smokers were 3.25 times more likely to develop oral cancer than those without the disorder. Dr Raphael Cuomo, an anesthesiology professor at UC San Diego School of Medicine who led the analysis, said: 'Cannabis smoke contains many of the same carcinogenic compounds found in tobacco smoke, which have known damaging effects on the epithelial tissue that lines the mouth.' Cannabis smoke packs a heavy load of toxic chemicals and carcinogens, about 2,600 of them, similar to tobacco smoke. But researchers are only recently getting a fuller understanding of what those chemicals are. They now know that marijuana smoke contains hundreds of polycyclic aromatic hydrocarbons (PAHs), benzene, and ammonia. These chemicals adhere to mucus membranes in the mouth, enabling carcinogens to seep into oral tissue. Meanwhile, THC, the psychoactive chemical in marijuana, can suppress crucial immune system pathways that would typically patrol for, and kill, those rogue cells. Of the more than 45,000 patients included in the study, 949 had cannabis use disorder. The group that did not smoke or smoked only occasionally remained either weed free or only occasional users over the five-year study. Over 97 percent were still abstinent or infrequent users by the time researchers followed up. During the study, 106 patients were diagnosed with oral cancer. Among people without CUD, the rate of oral cancer was 0.23 percent, which matches general population rates. However, among participants with CUD, 0.74 percent developed oral cancer. Oral cancer includes cancerous growths that develop in the mouth and throat, including the lips, tongue, gums, the floor of the mouth and the roof of the mouth. About one in 59 men and 1 in 139 women will develop oral cancer at some point in their lives. Oral cancers account for about three percent of cancers diagnosed in the US every year, with about 58,500 diagnoses and 12,250 deaths annually. Researchers said their findings will have implications for cancer screening practices in primary care and mental health settings, as patients with CUD often present with overlapping social and behavioral risk factors, including tobacco use, alcohol use, and a lower likelihood of engaging in preventive healthcare. People with CUD who were also tobacco users were 6.24 times more likely to get oral cancer. Age also played a role, with each additional year of age increasing cancer risk by about four times per year. Like tobacco smokers, marijuana smokers see damage to their lung and throat cells, leading to abnormal cell growth that can cause cancer and tissue changes. Those effects can occur in people who are not tobacco smokers, though, indicating that marijuana smoke can be just as harmful on its own as cigarette smoke. Dr Cuomo said: 'These findings add to a growing body of evidence suggesting that chronic or problematic cannabis use may contribute to cancer risk in tissues exposed to combustion products.' Their findings were published in the journal Preventive Medicine Reports. In the United States, marijuana is fully legal for recreational and medicinal use in 29 states. It is entirely illegal in four states. The majority of the public, about 88 percent, supports legalization, according to the Pew Research Center. But public health experts are raising concerns over potential long-term effects, of which scientists still do not have a complete understanding. In June, University of California researchers reviewed 24 studies involving 200million people to investigate the relationship between weed and cardiovascular disease, stroke and acute coronary syndrome (ACS) - a group of heart conditions in which there is reduced or blocked blood flow to the heart, such as a heart attack. They found there was a 29 percent higher risk of ACS among cannabis users, a 20 percent higher risk for stroke and double the risk of dying from cardiovascular disease, which includes coronary artery disease, heart failure and irregular heartbeats. Last month, findings from an FDA-run clinical trial were released, investigating dangerous liver enzyme spikes in people who consumed cannabis. The results showed that eight users of CBD, the substance derived from the hemp plant that's free of the psychoactive chemical THC, developed enzyme spikes above the safe threshold, raising the risk of chronic liver damage or failure. Seven people dropped out due to liver concerns between weeks three and four. However, everyone's liver tests normalized after quitting CBD. Meanwhile, regular use of potent cannabis in adolescence has been linked to long-term changes in brain structure, particularly in the prefrontal cortex, the region responsible for decision-making, emotional regulation, and impulse control. This is also the age when many psychotic disorders first appear. THC may trigger schizophrenia or psychotic episodes in individuals with genetic predispositions. A 2022 review by University of Bath researchers, which analyzed 20 studies involving 120,000 people, found users of high-potency cannabis were four times more likely to develop addiction and three to five times more likely to suffer a psychotic break compared to those using lower-potency strains. Earlier this year, a report in JAMA Network Open found that emergency room visits in Ontario, Canada, linked to schizophrenia in marijuana users tripled after legalization. Between 2006 and 2022, the rate of schizophrenia among those with cannabis use disorder climbed from four percent to over 10 percent. In contrast, just 0.6 percent of non-users developed the condition.
